Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
SaaS Adoption
SaaS Adoption indicates the level of adoption by this company of software as a service services.
Cloud Adoption
Cloud Adoption indicates the level of adoption by this company of cloud services.
IT Footprint
IT Footprint gives a relative indication of how much IT services this company consumes.
IT Spend
IT Spend shows roughly how much this client spends on IT per year in USD.
Enlyft tracks the use of over 15,000 technologies and has proprietary data on over 18 million companies worldwide.
Medivir AB uses 32 different technologies from 10 different vendors. They have above average use of several technologies including Tibco Spotfire, Veeam Backup & Replication and Veeam.
Medivir AB uses products from 10 different product categories. They are particularly heavy users of products in Software Frameworks, Content Delivery Network (CDN), and Enterprise Resource Planning (ERP).
Enlyft tracks the use of over 15,000 technologies and has proprietary data on over 18 million companies worldwide.
Technology | Category | Vendor | Usage |
---|---|---|---|
NetSuite | Enterprise Applications | Oracle | ![]() |
What other companies use NetSuite?